公开(公告)号：US20230042358A1

公开(公告)日：2023-02-09

申请号：US17413469

申请日：2019-12-11

申请人： Takeda Pharmaceutical Company Limited

发明人： Yuhei MIYANOHANA ,  Yuichi KAJITA ,  Tatsuki KOIKE ,  Yasutaka HOASHI ,  Yasushi HATTORI ,  Norihito TOKUNAGA ,  Tsuneo ODA ,  Tohru MIYAZAKI ,  Dilhumar UYGHUR ,  Yoshiteru ITO ,  Kohei TAKEUCHI ,  Keisuke IMAMURA ,  Takahiro SUGIMOTO ,  Koichiro FUKUDA ,  Yasuhisa KOHARA ,  Rei OKAMOTO ,  Taiichi OHRA ,  Naoki MIYAMOTO ,  Jun CHIBA ,  Yoshito TERAO ,  Masanori KAWASAKI

IPC分类号： C07D455/02 ,  A61P25/26 ,  C07D471/04 ,  C07D217/24 ,  C07D239/90 ,  C07D237/32 ,  C07D401/10 ,  C07D403/10 ,  C07D498/04 ,  C07D417/06 ,  C07D401/06

摘要： The present invention provides a heterocyclic compound having an orexin type 2 receptor agonist activity.
A compound represented by the formula (I): wherein each symbol is as described in the description, or a salt thereof has an orexin type 2 receptor agonist activity, and is useful as an agent for the prophylaxis or treatment of narcolepsy.